Epigenetics in Bladder Cancer: A Review of the Literature

Dogan, Tunay; YAZICI, HÜLYA

doi:10.5505/tjo.2021.2884

Epigenetics in Bladder Cancer: A Review of the Literature

Tunay Dogan, (İstanbul Üniversitesi, Onkoloji Enstitüsü, Kanser Genetiği Bölümü, Temel Onkoloji Anabilim Dalı, İstanbul, Türkiye)

Hülya YAZICI (İstanbul Arel Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı, İstanbul, Türkiye)

Türk Onkoloji Dergisi

5 0

Yıl: 2022 Cilt: 37 Sayı: 1 Sayfa Aralığı: 83 - 92 Metin Dili: İngilizce DOI: 10.5505/tjo.2021.2884 İndeks Tarihi: 29-10-2022

Epigenetics in Bladder Cancer: A Review of the Literature

Öz:

Bladder cancer (BC) is the 10th most frequent type of cancer worldwide, with around 549.000 new cases and 200.000 deaths/year and it has the highest incidence rates with a strong male and elderly predomi nance. Besides, BC is a significant burden on health-care systems in terms of long-term therapy due to its high risk of recurrence. The investigation for a biomarker that high sensitivity and specificity to be used in the diagnosis and follow-up of BC is still ongoing because cystoscopic imaging, which is currently using it as the gold-standard technique, is an invasive procedure. Opportunely, the recent epigenetic-based studies are provided successful results for this subject. Therefore, in this study, we review that the DNA methylation and microRNAs relationship with BC were investigated in the light of current studies in the literature, particularly using the meta-analyses. The evaluation of the association of BC with DNA methylation showed that the hypermethylation was parallel with the muscle invasion, increased tumor stage and grade, poor prognosis, and cancer-associated mortality. Other than, many researchers suggest that various genes or gene panels as the methylation-based biomarkers for use in the follow-up of BC. Similarly, the miRNA panels may successfully differentiate BC samples from healthy controls, and provide successful estimations for survival and recurrence. To all appearances, the increase of the number of epigenetic-based research in BC not only will provide useful data for clarifying the BC progression, but will also increase the number of biomarkers with high sensitivity and specificity.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.
2. Johansson S, Cohen S. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997;13(5):291–8.
3. Sanli O, Dobruch J, Knowles M, Burger M, Alemozaf far M, Nielsen ME, et al. Bladder cancer. Nat Rev Dis Primers 2017;3(1):1–19.
4. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robert son AG, Seiler R, et al. A consensus molecular clas sification of muscle-invasive bladder cancer. Eur Urol 2020;77(4):420–33.
5. Bladder cancer: Diagnosis and management of blad der cancer. BJU Int 2017;120(6):755–65.
6. Michalak E, Burr M, Bannister A, Dawson M. The roles of DNA, RNA and histone methylation in aging and cancer. Nat Rev Mol Cell Biol 2019;20(10):573–89.
7. Bai Z, Liu Q, Wang X, Liu W. APC promoter methy lation is correlated with development and progression of bladder cancer, but not linked to overall survival: A meta-analysis. Neoplasma 2019;66(3):470–80.
8. Zhan L, Zhang B, Tan Y, Yang C, Huang C, Wu Q, et al. Quantitative assessment of the relationship be tween RASSF1A gene promoter methylation and bladder cancer (PRISMA). Medicine (Baltimore) 2017;96(7):e6097.
9. Dai L, Ma C, Zhang Z, Zeng S, Liu A, Tang S, et al. DAPK promoter methylation and bladder cancer risk: A systematic review and meta-analysis. PLoS One 2016;11(12):e0167228.
10.Chen F, Huang T, Ren Y. Clinical significance of CDH13 promoter methylation as a biomarker for blad der cancer: A meta-analysis. BMC Urol 2016;16(1):52.
11.Yu Y, Cao H, Zhang M, Shi F, Wang R, Liu X. Prognos tic value of DNA methylation for bladder cancer. Clin Chim Acta 2018;484:207–12.
12.Yang Z, Liu A, Xiong Q, Xue Y, Liu F, Zeng S, et al. Prog nostic value of differentially methylated gene profiles in bladder cancer. J Cell Physiol 2019;234(10):18763–72.
13.Zhang Y, Fang L, Zang Y, Xu Z. Identification of core genes and key pathways via ıntegrated analysis of geneexpression and DNA methylation profiles in bladder cancer. Med Sci Monitor 2018;24:3024–33.
14.Bosschieter J, Nieuwenhuijzen J, Hentschel A, van Splunter AP, Segerink LI, Vis AN, et al. A two-gene methylation signature for the diagnosis of bladder cancer in urine. Epigenomics 2019;11(3):337–47.
15.Stubendorff B, Wilhelm K, Posselt K, Catto J, Hart mann A, Bertz B, et al. A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. J Cancer Res Clin Oncol 2019;145(4):811–20.
16.Leão R, Lee D, Figueiredo A, Hermanns T, Wild P, Komosa M, et al. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Int J Cancer. 2018;144(7):1676–84.
17.Guo R, Xiong G, Yang K, Zhang L, He SM, Gong YQ, et al. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothe lial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study. Urol Oncol Sem Original Investig 2018;36(7):342.e15–23.
18. van Kessel K, van der Keur K, Dyrskjøt L, Algaba F, Welvaart NY, Beukers W, et al. Molecular markers ın crease precision of the European association of urology non-muscle-ınvasive bladder cancer progression risk groups. Clin Cancer Research. 2018;24(7):1586– 93.
19.Shindo T, Shimizu T, Nojima M, Niinuma T, Maruyama R, Kitajima H, et al. Evaluation of urinary DNA methylation as a marker for recurrent bladder cancer: A 2-center prospective study. Urology 2018;113:71–8.
20.López J, Angulo J, Martín A, Sánchez-Chapado M, González-Corpas A, Colás B, et al. A DNA hyperme thylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder can cer. APMIS. 2017;125(9):787–96.
21.Husek P, Pacovsky J, Chmelarova M, Podhola M, Bro dak M. Methylation status as a predictor of intravesi cal Bacillus Calmette-Guérin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor. Biomed Papers 2017;161(2):210–6.
22.Jin F, Thaiparambil J, Donepudi S, Vantaku V, Pi yarathna DW, Maity S, et al. Tobacco-specific car cinogens ınduce hypermethylation, DNA adducts, and DNA damage in bladder cancer. Cancer Prev Res 2017;10(10):588–97.
23.Vantaku V, Amara C, Piyarathna D, Donepudi SR, Ambati CR, Putluri V, et al. DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. Car cinogenesis 2019;40(11):1332–40.
24.Huang Y, Shen X, Zou Q, Wang S, Tang S, Zhang G. Bi ological functions of microRNAs: A review. J Physiol Biochem 2010;67(1):129–39.
25.Rothschild S. MicroRNA therapies in cancer. Mol Cell Ther 2014;2(1):7.
26.Xie Y, Ma X, Chen L. MicroRNAs with prognostic sig nificance in bladder cancer: A systematic review and meta-analysis. Sci Rep. 2017;7(1):41.
27.Chen Z, Zhan Y, Chi J, Guo S, Zhong X, He A, et al. Using microRNAs as novel predictors of urologic can cer survival: An ıntegrated analysis. EBioMedicine 2018;34:94–107.
28.Yang F, Li H, Li T, Zhao Y, Liu Z, Li X. Prognostic value of MicroRNA-15a in human cancers: A meta-analysis and bioinformatics. Biomed Res Int 2019;2019:1– 12.
29.Shi H, Yu J, Yu J, Feng Z, Zhang C, Li GY, et al. Diag nostic significance of microRNAs as novel biomark ers for bladder cancer: A meta-analysis of ten articles. World J Surg Oncol 2017;15(1):147.
30.Xiao S, Wang J, Xiao N. MicroRNAs as noninvasive biomarkers in bladder cancer detection: A diagnos tic meta-analysis based on qRT-PCR data. Int J Biol Markers 2016;31(3):276–85.
31.Ouyang H, Zhou Y, Zhang L, Shen G. Diagnostic value of MicroRNAs for urologic cancers. Medicine (Balti more) 2015;94(37):e1272.
32.Zabolotneva A, Zhavoronkov A, Garazha A, Roumi antsev S, Buzdin A. Characteristic patterns of mi croRNA expression in human bladder cancer. Front Genet 2013;3:310.
33.Lin S, Choe J, Du P, Triboulet R, Gregory R. The m 6 a methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell 2016;62(3):335–45.
34.Han J, Wang J, Yang X, Yu H, Zhou R, Lu HC, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer 2019;18(1):110.
35.Lu Q, Liu T, Feng H, Yang R, Zhao X, Chen W, et al. Circular RNA circSLC8A1 acts as a sponge of miR 130b/miR-494 in suppressing bladder cancer progres sion via regulating PTEN. Mol Cancer 2019;18(1):111.
36.Hou G, Xu W, Jin Y, Wu J, Pan Y, Zhou F. MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D. Biochem Biophys Res Commun 2019;519(4):747–53.
37.Lin T, Zhou S, Gao H, Li Y, Sun L. MicroRNA-325 ıs a potential biomarker and tumor regulator in human bladder cancer. Technol Cancer Res Treat 2018;17:536.
38.Tian H, Wang X, Lu J, Tian W, Chen P. MicroRNA-621 inhibits cell proliferation and metastasis in bladder cancer by suppressing Wnt/β-catenin signaling. Chem Biol Interact 2019;308:244–51.
39.Feng Y, Kang Y, He Y, Liu J, Liang B, Yang P, et al. Mi croRNA-99a acts as a tumor suppressor and is down regulated in bladder cancer. BMC Urol. 2014;14(1):50.
40.Wu D, Niu X, Tao J, Li P, Lu Q, Xu A, et al. MicroRNA 379-5p plays a tumor-suppressive role in human blad der cancer growth and metastasis by directly targeting MDM2. Oncol Rep 2017;37(6):3502–8.
41.Jiang H, Bu Q, Zeng M, Xia D, Wu A. MicroRNA-93 promotes bladder cancer proliferation and invasion by targeting PEDF. Urol Oncol Sem Original Investig. 2019;37(2):150–7.
42.Witjes J, Morote J, Cornel E, Gakis G, van Valen berg FJ, Lozano F, et al. Performance of the bladder EpiCheck™ methylation test for patients under surveil lance for non-muscle-invasive bladder cancer: Results of a multicenter, prospective, blinded clinical trial. Eur Urol Oncol 2018;1(4):307–13.

APA	Dogan T, YAZICI H (2022). Epigenetics in Bladder Cancer: A Review of the Literature. , 83 - 92. 10.5505/tjo.2021.2884
Chicago	Dogan Tunay,YAZICI HÜLYA Epigenetics in Bladder Cancer: A Review of the Literature. (2022): 83 - 92. 10.5505/tjo.2021.2884
MLA	Dogan Tunay,YAZICI HÜLYA Epigenetics in Bladder Cancer: A Review of the Literature. , 2022, ss.83 - 92. 10.5505/tjo.2021.2884
AMA	Dogan T,YAZICI H Epigenetics in Bladder Cancer: A Review of the Literature. . 2022; 83 - 92. 10.5505/tjo.2021.2884
Vancouver	Dogan T,YAZICI H Epigenetics in Bladder Cancer: A Review of the Literature. . 2022; 83 - 92. 10.5505/tjo.2021.2884
IEEE	Dogan T,YAZICI H "Epigenetics in Bladder Cancer: A Review of the Literature." , ss.83 - 92, 2022. 10.5505/tjo.2021.2884
ISNAD	Dogan, Tunay - YAZICI, HÜLYA. "Epigenetics in Bladder Cancer: A Review of the Literature". (2022), 83-92. https://doi.org/10.5505/tjo.2021.2884

APA	Dogan T, YAZICI H (2022). Epigenetics in Bladder Cancer: A Review of the Literature. Türk Onkoloji Dergisi, 37(1), 83 - 92. 10.5505/tjo.2021.2884
Chicago	Dogan Tunay,YAZICI HÜLYA Epigenetics in Bladder Cancer: A Review of the Literature. Türk Onkoloji Dergisi 37, no.1 (2022): 83 - 92. 10.5505/tjo.2021.2884
MLA	Dogan Tunay,YAZICI HÜLYA Epigenetics in Bladder Cancer: A Review of the Literature. Türk Onkoloji Dergisi, vol.37, no.1, 2022, ss.83 - 92. 10.5505/tjo.2021.2884
AMA	Dogan T,YAZICI H Epigenetics in Bladder Cancer: A Review of the Literature. Türk Onkoloji Dergisi. 2022; 37(1): 83 - 92. 10.5505/tjo.2021.2884
Vancouver	Dogan T,YAZICI H Epigenetics in Bladder Cancer: A Review of the Literature. Türk Onkoloji Dergisi. 2022; 37(1): 83 - 92. 10.5505/tjo.2021.2884
IEEE	Dogan T,YAZICI H "Epigenetics in Bladder Cancer: A Review of the Literature." Türk Onkoloji Dergisi, 37, ss.83 - 92, 2022. 10.5505/tjo.2021.2884
ISNAD	Dogan, Tunay - YAZICI, HÜLYA. "Epigenetics in Bladder Cancer: A Review of the Literature". Türk Onkoloji Dergisi 37/1 (2022), 83-92. https://doi.org/10.5505/tjo.2021.2884